We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » South Korea’s Hanmi Signs Lucrative Drug Licensing Deals With Two Companies
South Korea’s Hanmi Signs Lucrative Drug Licensing Deals With Two Companies
French drugmaker Sanofi is looking to future-proof its diabetes franchise by in-licensing rights to a trio of next-generation diabetes medicines from South Korea’s Hanmi in a deal worth up to $4.2 billion.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor